Polycythemia vera (PV) Program in Pharmaceutical Benefits Scheme (PBS) 012-25080641
Expand allThis document outlines details of PBS-subsidised PBS-subsidised ruxolitinib for patients with polycythemia vera (PV).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
Polycythemia vera (PV) quick reference
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial PB388 form | Written Electronic S85: ruxolitinib | No | OPA | Not specified | Yes |
Balance of initial (up to 48 weeks) | Telephone Electronic S85: ruxolitinib | No | OPA | Not specified | Yes |
First continuing | Telephone Electronic S85: ruxolitinib | No | OPA | Not specified | Yes |
Subsequent continuing | Telephone Electronic S85: ruxolitinib | No | OPA | Not specified | Yes |